The emerging genomic landscape of endometrial cancer

Clinical Chemistry

Volumn 60, Issue 1, 2014, Pages 98-110

  Le Gallo, Matthieu ^a   Bell, Daphne W ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 4; EPITHELIAL CELL ADHESION MOLECULE; FIBROBLAST GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53;

CANCER MORTALITY; COPY NUMBER VARIATION; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; GENE MAPPING; GENE MUTATION; HISTOPATHOLOGY; HUMAN; REVIEW; SOMATIC MUTATION; TUMOR CLASSIFICATION;

EID: 84891791669     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.205740     Document Type: Review

References (75)

1. American Cancer Society. Cancer facts & figures 2013. http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/ document/ acspc-036845.pdf (Accessed October 2013). 60 p.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 2010;127: 2893-917.
3. Tropé CG, Abeler VM, Kristensen GB. Diagnosis and treatment of sarcoma of the uterus. A review. Acta Oncol 2012;51: 694-705.
4. Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubik-Nuch RA, Tavassoli FA. Tumors of the uterine corpus. In: Tavassoli FA, Devilee P, eds. World Health Organization classification of tumours: pathology and genetics of tumors of the breast and female genital organs. Lyon: IARC Press; 2003. p 221-32.
5. Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol 2012;13:e353-61.
6. Long B, Liu FW, Bristow RE. Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States. Gynecol Oncol 2013;130: 652-9.
7. Long J, Zheng W, Xiang YB, Lose F, Thompson D, Tomlinson I, et al. Genome-wide association study identifies a possible susceptibility locus for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2012;21: 980-7.
8. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18: 400-7.
9. Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. Hereditary factors in cancer. Study of two large Midwestern kindreds. Arch Intern Med 1966;117: 206-12.
10. Vasen HF, Offerhaus GJ, den Hartog Jager FC, Menko FH, Nagengast FM, Griffioen G, et al. The tumour spectrum in hereditary non-polyposis colorectal cancer: a study of 24 kindreds in the Netherlands. Int J Cancer 1990;46: 31-4. (Pubitemid 20225783)
11. Huang M, Djordjevic B, Yates MS, Urbauer D, Sun C, Burzawa J, et al. Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome. Cancer 2013;119: 3027-33.
12. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2013;45: 136-44.
13. Lavie O, Ben-Arie A, Segev Y, Faro J, Barak F, Haya N, et al. BRCA germline mutations in women with uterine serous carcinoma - still a debate. Int J Gynecol Cancer 2010;20: 1531-4.
14. Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol 2013;130: 127-31.
15. The Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73.
16. Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 2012;104: 1503-13.
17. Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, et al. Landscape of somatic singlenucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A 2013; 110: 2916-22.
18. Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 2012; 44: 1310-5.
19. Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih IM, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013;5:167ra4.
20. Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 2012;22: 2120-9.
21. Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 2011;8: 261-71.
22. Mahboubi E, Eyler N, Wynder EL. Epidemiology of cancer of the endometrium. Clin Obstet Gynecol 1982;25: 5-17. (Pubitemid 12112195)
23. Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, et al. Type I and II endometrial cancers: Have they different risk factors? J Clin Oncol 2013;31: 2607-18.
24. O'Hara AJ, Bell DW. The genomics and genetics of endometrial cancer. Adv Genomics Genet 2012;2012: 33-47.
25. Lewin SN, Herzog TJ, Barrena Medel NI, Deutsch I, Burke WM, Sun X, Wright JD. Comparative performance of the 2009 International Federation of Gynecology and Obstetrics' staging system for uterine corpus cancer. Obstet Gynecol 2010;116: 1141-9.
26. Bradford LS, Rauh-Hain JA, Schorge J, Birrer MJ, Dizon DS. Advances in the management of recurrent endometrial cancer. Am J Clin Oncol [Epub ahead of print 2013 Jun 11].
27. Pere H, Tapper J, Wahlstrom T, Knuutila S, Butzow R. Distinct chromosomal imbalances in uterine serous and endometrioid carcinomas. Cancer Res 1998;58: 892-5. (Pubitemid 28182453)
28. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57: 4736-8. (Pubitemid 27468978)
29. Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, Bell DW. A unique spectrum of somatic PIK3CA (p110α) mutations within primary endometrial carcinomas. Clin Cancer Res 2011;17: 1331-40.
30. Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res 2011;71: 4061-7.
31. Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011;1: 170-85.
32. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005;65: 10669-73. (Pubitemid 41713332)
33. Werner HM, Berg A, Wik E, Birkeland E, Krakstad C, Kusonmano K, et al. ARID1A loss is prevalent in endometrial hyperplasia with atypia and lowgrade endometrioid carcinomas. Mod Pathol 2013;26: 428-34.
34. Bosse T, Ter Haar NT, Seeber LM, Diest PJ, Hes FJ, Vasen HF, et al. Loss of ARID1A expression and its relationship with PI3K-AKT pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol 2013;26: 1525-35.
35. Rahman M, Nakayama K, Rahman MT, Katagiri H, Katagiri A, Ishibashi T, et al. Clinicopathologic analysis of loss of AT-rich interactive domain 1a expression in endometrial cancer. Human Pathol 2013;44: 103-9.
36. Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One 2012; 7:e30801.
37. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007;26: 7158-62. (Pubitemid 350059681)
38. Machin P, Catasus L, Pons C, Munoz J, Matias- Guiu X, Prat J. CTNNB1 mutations and β-catenin expression in endometrial carcinomas. Hum Pathol 2002;33: 206-12. (Pubitemid 34298736)
39. Schlosshauer PW, Ellenson LH, Soslow RA. β-Catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol 2002;15: 1032-7.
40. Goodfellow PJ, Buttin BM, Herzog TJ, Rader JS, Gibb RK, Swisher E, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A 2003;100: 5908-13. (Pubitemid 36576906)
41. Esteller M, Catasus L, Matias-Guiu X, Mutter GL, Prat J, Baylin SB, Herman JG. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 1999; 155: 1767-72.
42. Simpkins SB, Bocker T, Swisher EM, Mutch DG, Gersell DJ, Kovatich AJ, et al. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet 1999;8: 661-6. (Pubitemid 29139981)
43. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J. SEER survival monograph: cancer survival among adults: U.S. SEER Program, 1988-2001. Patient and tumor characteristics. Bethesda (MD): National Cancer Institute, SEER Program; 2007. NIH Pub. No. 07-6215.
44. Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006;94: 642-6. (Pubitemid 43361894)
45. Fadare O, Zheng W. Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach. Am J Cancer Res 2012;2: 335-9.
46. Moore KN, Fader AN. Uterine papillary serous carcinoma. Clin Obstet Gynecol 2011;54: 278-91.
47. del Carmen MG, Birrer M, Schorge JO. Uterine papillary serous cancer: a review of the literature. Gynecol Oncol 2012;127: 651-61.
48. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26: 1268-74.
49. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150: 177-85. (Pubitemid 27027108)
50. Wild PJ, Ikenberg K, Fuchs TJ, Rechsteiner M, Georgiev S, Fankhauser N, et al. p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans. EMBO Mol Med 2012;4: 808-24.
51. Clarke BA, Gilks CB. Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. J Clin Pathol 2010; 63: 410-5.
52. Gilks CB, Oliva E, Soslow RA. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol 2013;37: 874-81.
53. Soslow RA. High-grade endometrial carcinomas- strategies for typing. Histopathology 2013;62: 89-110.
54. Darvishian F, Hummer AJ, Thaler HT, Bhargava R, Linkov I, Asher M, Soslow RA. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol 2004;28: 1568-78. (Pubitemid 39564961)
55. Yemelyanova A, Ji H, Shih IeM, Wang TL, Wu LS, Ronnett BM. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol 2009;33: 1504-14.
56. Alkushi A, Kobel M, Kalloger SE, Gilks CB. Highgrade endometrial carcinoma: Serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol 2010;29: 343-50.
57. Alvarez T, Miller E, Duska L, Oliva E. Molecular profile of grade 3 endometrioid endometrial carcinoma: Is it a type I or type II endometrial carcinoma? Am J Surg Pathol 2012;36: 753-61.
58. McConechy MK, Ding J, Cheang MC, Wiegand K, Senz J, Tone A, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol 2012;228: 20-30.
59. Pursell ZF, Kunkel TA. DNA polymerase ε: a polymerase of unusual size (and complexity). Prog Nucleic Acid Res Mol Biol 2008;82: 101-45.
60. Church DN, Briggs SE, Palles C, Domingo E, Kearsey SJ, Grimes JM, et al. DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer. Hum Mol Genet 2013;22: 2820-8.
61. Zighelboim I, Goodfellow PJ, Gao F, Gibb RK, Powell MA, Rader JS, Mutch DG. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol 2007;25: 2042-8. (Pubitemid 46972789)
62. An HJ, Kim KI, Kim JY, Shim JY, Kang H, Kim TH, et al. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators. Am J Surg Pathol 2007;31: 846-53. (Pubitemid 47165137)
63. Konopka B, Janiec-Jankowska A, Czapczak D, Paszko Z, Bidzinski M, Olszewski W, Goluda C. Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations. J Cancer Res Clin Oncol 2007;133: 361-71. (Pubitemid 46716700)
64. Black D, Soslow RA, Levine DA, Tornos C, Chen SC, Hummer AJ, et al. Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol 2006;24: 1745-53. (Pubitemid 46622146)
65. Moreno-Bueno G, Rodriguez-Perales S, Sá nchez- Esté vez C, Marcos R, Hardisson D, Cigudosa JC, Palacios J. Molecular alterations associated with cyclin D1 overexpression in endometrial cancer. Int J Cancer 2004;110: 194-200. (Pubitemid 38580390)
66. Novetsky AP, Zighelboim I, Thompson DM Jr, Powell MA, Mutch DG, Goodfellow PJ. Frequent mutations in the RPL22 gene and its clinical and functional implications. Gynecol Oncol 2013;128: 470-4.
67. Rao S, Lee SY, Gutierrez A, Perrigoue J, Thapa RJ, Tu Z, et al. Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, lin28b. Blood 2012;120: 3764-73.
68. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 2012;18: 5856-64.
69. Diaz-Padilla I, Romero N, Amir E, Matias-Guiu X, Vilar E, Muggia F, Garcia-Donas J. Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2013;88: 154-67.
70. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancerassociated genes. Nature 2013;499: 214-8.
71. Newbury R, Schuerch C, Goodspeed N, Fanning J, Glidewell O, Evans M. DNA content as a prognostic factor in endometrial carcinoma. Obstet Gynecol 1990;76: 251-7. (Pubitemid 20227467)
72. Prat J, Oliva E, Lerma E, Vaquero M, Matias-Guiu X. Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content. Cancer 1994;74: 1778-83. (Pubitemid 24301833)
73. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12: 395-402. (Pubitemid 47539306)
74. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008;68: 9221-30.
75. El-Sahwi KS, Schwartz PE, Santin AD. Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. Expert Rev Anticancer Ther 2012;12: 41-9.